Sinovac Biotech Ltd Cash Flow-to-Debt Ratio
Sinovac Biotech Ltd cash flow-to-debt ratio. Sinovac Biotech Ltd (SVA) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2023, meaning its operating cash flow of $146.01 Million could theoretically repay 0% of its total liabilities ($1.64 Billion) in one year. Check Sinovac Biotech Ltd (SVA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sinovac Biotech Ltd (2000–2025)
Cash flow-to-debt ratio of Sinovac Biotech Ltd from 2000 to 2025. Historical debt coverage capacity for Sinovac Biotech Ltd across 26 annual periods. Check SVA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Sinovac Biotech Ltd Cash Flow-to-Debt Ratio by Year (2000–2025)
Sinovac Biotech Ltd cash flow-to-debt ratio by year from 2000 to 2025. Year-by-year debt coverage analysis for Sinovac Biotech Ltd. For the full cash flow conversion analysis, see SVA cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.23x | $-510.49 Million | $2.23 Billion | ▼ -721.2% |
| 2024 | -0.03x | $-56.89 Million | $2.04 Billion | ▼ -142.9% |
| 2023 | 0.06x | $106.02 Million | $1.64 Billion | ▲ +111.8% |
| 2022 | -0.55x | $-770.75 Million | $1.40 Billion | ▼ -110.3% |
| 2021 | 5.35x | $15.35 Billion | $2.87 Billion | ▲ +771.2% |
| 2020 | 0.61x | $479.31 Million | $781.20 Million | ▲ +57.2% |
| 2019 | 0.39x | $39.07 Million | $100.10 Million | ▲ +282.6% |
| 2018 | 0.10x | $7.94 Million | $77.85 Million | ▼ -86.1% |
| 2017 | 0.73x | $59.76 Million | $81.69 Million | ▲ +486.5% |
| 2016 | -0.19x | $-15.46 Million | $81.69 Million | ▼ -398.5% |
| 2015 | 0.06x | $4.21 Million | $66.42 Million | ▲ +160.6% |
| 2014 | -0.10x | $-10.13 Million | $96.80 Million | ▼ -282.1% |
| 2013 | 0.06x | $5.58 Million | $97.05 Million | ▲ +128.0% |
| 2012 | -0.20x | $-16.25 Million | $79.33 Million | ▼ -203.8% |
| 2011 | 0.20x | $13.94 Million | $70.61 Million | ▲ +192.1% |
| 2010 | -0.21x | $-14.28 Million | $66.60 Million | ▼ -127.0% |
| 2009 | 0.79x | $48.41 Million | $61.01 Million | ▲ +79.8% |
| 2008 | 0.44x | $10.50 Million | $23.80 Million | ▲ +151.0% |
| 2007 | 0.18x | $4.32 Million | $24.55 Million | ▲ +268.8% |
| 2006 | -0.10x | $-1.64 Million | $15.70 Million | ▲ +36.8% |
| 2005 | -0.16x | $-1.13 Million | $6.86 Million | ▲ +26.5% |
| 2004 | -0.22x | $-1.54 Million | $6.86 Million | ▲ +47.8% |
| 2003 | -0.43x | $-1.72 Million | $4.01 Million | ▼ -1.3% |
| 2002 | -0.42x | $-58.05K | $136.81K | ▲ +18.4% |
| 2001 | -0.52x | $-494.80K | $952.15K | ▲ +0.0% |
| 2000 | -0.52x | $-494.80K | $952.15K | — |